Arbutus Biopharma Statistics
Total Valuation
ABUS has a market cap or net worth of $907.69 million. The enterprise value is $818.69 million.
| Market Cap | 907.69M |
| Enterprise Value | 818.69M |
Important Dates
The next confirmed earnings date is Wednesday, August 12, 2026, before market open.
| Earnings Date | Aug 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ABUS has 197.54 million shares outstanding. The number of shares has increased by 2.21% in one year.
| Current Share Class | 197.54M |
| Shares Outstanding | 197.54M |
| Shares Change (YoY) | +2.21% |
| Shares Change (QoQ) | +1.16% |
| Owned by Insiders (%) | 0.73% |
| Owned by Institutions (%) | 50.05% |
| Float | 120.16M |
Valuation Ratios
The trailing PE ratio is 5.83.
| PE Ratio | 5.83 |
| Forward PE | n/a |
| PS Ratio | 4.85 |
| Forward PS | 314.41 |
| PB Ratio | 3.57 |
| P/TBV Ratio | 3.41 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 5.17 |
| EV / Sales | 4.36 |
| EV / EBITDA | 5.31 |
| EV / EBIT | 5.32 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 81.42, with a Debt / Equity ratio of 0.01.
| Current Ratio | 81.42 |
| Quick Ratio | 80.97 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | 0.02 |
| Debt / FCF | n/a |
| Interest Coverage | 1,960.46 |
Financial Efficiency
Return on equity (ROE) is 89.58% and return on invested capital (ROIC) is 52.60%.
| Return on Equity (ROE) | 89.58% |
| Return on Assets (ROA) | 48.84% |
| Return on Invested Capital (ROIC) | 52.60% |
| Return on Capital Employed (ROCE) | 55.05% |
| Weighted Average Cost of Capital (WACC) | 7.54% |
| Revenue Per Employee | $9.56M |
| Profits Per Employee | $8.06M |
| Employee Count | 19 |
| Asset Turnover | 0.96 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +35.52% in the last 52 weeks. The beta is 0.60, so ABUS's price volatility has been lower than the market average.
| Beta (5Y) | 0.60 |
| 52-Week Price Change | +35.52% |
| 50-Day Moving Average | 4.53 |
| 200-Day Moving Average | 4.45 |
| Relative Strength Index (RSI) | 50.20 |
| Average Volume (20 Days) | 1,334,847 |
Short Selling Information
The latest short interest is 19.65 million, so 9.95% of the outstanding shares have been sold short.
| Short Interest | 19.65M |
| Short Previous Month | 17.11M |
| Short % of Shares Out | 9.95% |
| Short % of Float | 16.36% |
| Short Ratio (days to cover) | 9.63 |
Income Statement
In the last 12 months, ABUS had revenue of $181.72 million and earned $153.05 million in profits. Earnings per share was $0.79.
| Revenue | 181.72M |
| Gross Profit | 156.48M |
| Operating Income | 147.43M |
| Pretax Income | 153.05M |
| Net Income | 153.05M |
| EBITDA | 149.04M |
| EBIT | 149.00M |
| Earnings Per Share (EPS) | $0.79 |
Balance Sheet
The company has $92.63 million in cash and $3.63 million in debt, with a net cash position of $89.00 million or $0.45 per share.
| Cash & Cash Equivalents | 92.63M |
| Total Debt | 3.63M |
| Net Cash | 89.00M |
| Net Cash Per Share | $0.45 |
| Equity (Book Value) | 258.73M |
| Book Value Per Share | 1.31 |
| Working Capital | 270.52M |
Cash Flow
| Operating Cash Flow | -24.63M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 44,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -24.63M |
| FCF Per Share | -$0.12 |
Margins
Gross margin is 86.11%, with operating and profit margins of 81.13% and 84.23%.
| Gross Margin | 86.11% |
| Operating Margin | 81.13% |
| Pretax Margin | 84.23% |
| Profit Margin | 84.23% |
| EBITDA Margin | 82.02% |
| EBIT Margin | 81.99% |
| FCF Margin | n/a |
Dividends & Yields
ABUS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.21% |
| Shareholder Yield | -2.21% |
| Earnings Yield | 17.37% |
| FCF Yield | -2.80% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | 60.54% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 6 |